This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myelogenous leukemia (AML)	Isocitrate dehydrogenase 1 (IDH1); IDH2	<p>A study in cell culture suggests that <i>R</i>(-)-2-hydroxyglutarate (2HG) levels could serve as diagnostic markers for AML. Studies in serum samples from AML patients identified correlations between mutations in IDH1 or IDH2 and increased levels of 2HG, the catalytic product of IDH1 and IDH2 ($p < 0.05$). In 78 AML patients, 15.4% and 7.7% had mutations in IDH2 and IDH1, respectively. Ongoing work includes developing a 2HG-based method for diagnosing AML.</p> <p>Agios Pharmaceuticals is evaluating the potential of 2HG as a diagnostic marker for gliomas.</p> <p>SciBX 3(12); doi:10.1038/scibx.2010.367 Published online March 25, 2010</p>	Patent and licensing status unavailable	<p>Ward, P. <i>et al. Cancer Cell</i>; published online March 15, 2010; doi:10.1016/j.ccr.2010.01.020</p> <p>Contact: Craig B. Thompson, University of Pennsylvania, Philadelphia, Pa. e-mail: craig@mail.med.upenn.edu</p>